KUWAIT DRUGS

 

SEARCH

 

SUGGESTIONS

 

ADD PRODUCTS

 

HOME

0-9    A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

 

 

PREVIOUS

  

NEXT

 
 

ZENAPAX 25 MG/5 ML VIALS

 

 
 

 

GENERIC NAMES

MANUFACTURERS 

MEDICAL GROUP

MEDICAL ARTICLES

 

DRUGS IN :

 

 

FDA DRUGS

UNITED STATES

CANADA

UNITED KINGDOM

AUSTRALIA

GERMANY

FRANCE

MIDDLE EAST

KUWAIT

LEBANON

EGYPT

SYRIA

BAHRAIN

IRAN

JORDAN

SAUDI ARABIA

UNITED ARAB EMIRATES

 

 

 
 

SIZE:

25 MG/5 ML

 

GENERIC NAME:

DACLIZUMAB

 

MANUFACTURER:

F. HUFFMANN LA ROCHE

 

UNIT:

 

ADMINISTRATION ROUTE:

 

FDA PREGNANCY GROUP:

C

 

INDICATIONS:

Rejection, renal transplant, prophylaxis

 

SIDE EFFECTS:

Chest pain

dyspnea

fever

hypertension

hypotension

nausea

peripheral edema

pulmonary edema

tachycardia

tremor

vomiting

weakness

wound infection

Hyperglycemia

Arthralgia

constipation

diarrhea

dizziness

dyspepsia

headache

insomnia

myalgia

slow wound healing

 

ABSOLUTE CONTRAINDICATIONS :

 

RELATIVE CONTRAINDICATIONS :

Diabetes mellitus

Infection

Malignancy, current

 

ADULT DOSE:

Transplant rejection, kidney (prophylaxis)- Intravenous infusion over fifteen minutes, 1 mg per kg of body weight every fourteen days for five doses beginning no earlier than twenty-four hours prior to transplantation .

 

MAXIMUM ADULT DOSE:

 

PEDIATRIC DOSE:

Transplant rejection, kidney (prophylaxis)- Intravenous infusion over fifteen minutes, 1 mg per kg of body weight every fourteen days for five doses beginning no earlier than twenty-four hours prior to transplantation . 

 

MAXIMUM PEDIATRIC DOSE:

 

ELDERLY DOSE:

Transplant rejection, kidney (prophylaxis)- Intravenous infusion over fifteen minutes, 1 mg per kg of body weight every fourteen days for five doses beginning no earlier than twenty-four hours prior to transplantation .

 

 

PREVIOUS

  

NEXT